| Literature DB >> 25896433 |
Julanda Al Mawly1, Alex Grinberg2, Niluka Velathanthiri3, Nigel French4.
Abstract
BACKGROUND: The estimation of the prevalence and zoonotic potential of Cryptosporidium parvum cycling in bovine populations requires the use of genotyping, as several morphologically similar non-parvum genetic variants of unproven clinical and public health impact are found in cattle. However, robust C. parvum prevalence estimates in cattle are lacking and comparative data of bovine and human isolates collected from the same regions are scarce. Thus, the relative contribution of the C. parvum oocysts released by farmed animals to animal and human cryptosporidiosis burden is, in general, poorly understood.Entities:
Mesh:
Year: 2015 PMID: 25896433 PMCID: PMC4423479 DOI: 10.1186/s13071-015-0855-9
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
The number of isolates for each bilocus genotype (BLG) identified in calves (the number of dairy farms is in brackets) and in historic human clinical isolates, sorted by their regions of origin
|
|
|
|
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| - | - | - | - | - | - | - | - | 2 (2) | - | - | - | - | - | - | 2 |
|
| - | - | 2 (2) | - | - | - | - | - | - | - | 1 (1) | - | - | 6 | 4 | 13 |
|
| 1 (1) | 5 | 6 (5) | 22 | - | - | 2 (2) | 5 | 1 (1) | - | 22 (14) | 3 | - | - | 30 | 97 |
|
| 1 (1) | - | 2 (1) | 1 | 3 (1) | - | 2 (1) | 2 | - | - | 1 (1) | 36 | - | 1 | 60 | 109 |
|
| - | - | - | - | - | - | - | - | 6 (2) | - | - | - | - | - | - | 6 |
|
| - | - | - | - | - | - | - | - | - | - | - | 1 | - | 1 | - | 2 |
|
| - | - | - | - | - | - | - | - | 2 (1) | - | - | - | - | - | - | 2 |
|
| - | - | - | 21 | - | - | 1 (1) | 11 | 4 (3) | 4 | 1 (1) | 1 | - | 2 | 20 | 65 |
|
| - | - | - | 1 | - | - | 4(2) | 1 | - | 5 | 1 (1) | 3 | - | - | 7 | 22 |
|
| - | - | 3 (2) | - | 1 (1) | - | - | - | - | - | - | - | - | - | - | 4 |
|
| - | - | 2 (2) | - | 1 (1) | - | - | - | - | - | - | - | - | - | - | 3 |
|
| - | - | 1 (1) | - | - | - | 3 (3) | - | - | - | - | - | - | - | - | 4 |
|
| - | - | - | - | - | - | 1 (1) | - | - | - | - | - | - | - | - | 1 |
|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 | 2 |
|
| - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | 1 |
|
| - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | 1 | 2 |
|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | 1 |
|
| - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|
| - | - | - | 2 | - | - | - | - | - | - | - | - | - | - | 1 | 3 |
|
| - | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | 1 |
|
| - | 1 | - | 2 | - | - | - | 1 | - | - | - | - | - | - | 2 | 6 |
|
| - | - | - | 7 | - | - | - | - | - | - | - | - | - | - | - | 7 |
|
| - | - | - | 5 | - | - | - | - | - | - | - | - | - | - | - | 5 |
|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5 | 5 |
|
| - | - | - | - | - | - | - | 2 | - | - | - | - | - | - | 1 | 3 |
|
| - | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 6 | 7 |
|
| 1 | 1 | ||||||||||||||
BLGs are defined using the gp60 nomenclature suggested by Sulaiman et al. [21], followed by the Hsp70 allele designation. Hsp70 alleles are designated by the number of 12-base repeat units (11 or 12) present in the sequence. Subscripts ‘v’, v1, v2 indicate variant sequences. BLGs containing gp60 alleles which in 2010 were found in humans only are followed by an asterisk.